LEO Pharma further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine
Ballerup, Denmark, 28 January, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that Thomas Hultsch, M.D., Ph.D., has been appointed as Head of Translational Medicine as of 28 January, 2019.
Thomas Hultsch’s primary task will be to build LEO Pharma’s foothold in Translational Medicine across the US and Europe and lead the establishment of a new Translational Medicine group in Boston.
The appointment of Thomas Hultsch underpins LEO Pharma’s objective to take the global lead in translational dermatology and immunology, among other by strengthening the way the company uses novel technologies in building a precision medicine platform, and by translating scientific and patient insights to further build the company’s disease understanding. Earlier this month, LEO Pharma also announced the appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor in Translational Medicine.
“At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that. It will strengthen LEO Pharma as a science driven organization by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly,” said Kim Kjoeller, Executive Vice President for Global Research and Development at LEO Pharma.
“Thomas Hultsch comes to LEO Pharma with an extensive network within immune dermatology in the US and Europe as well as an impressive track record of initiating successful scientific collaborations. With his appointment as Head of LEO Pharma’s new Translational Medicine Unit in Boston, we are ready to take translational medicine at LEO Pharma to the next level in terms of being a science driven and patient focused company,” said Per Sproegel, Vice President, Medical Science at LEO Pharma.
Thomas Hultsch is a Doctor of Medicine, a board-certified Dermatologist and Allergist and received his venia legendi for immunology from the Johannes Gutenberg University in Mainz, Germany. He trained as a post-doc and fellow at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland focusing on molecular biology, cell biology and clinical immunology/allergy.
He comes from a position as Senior Director for Translational Medicine at Sanofi US, where he successfully built and operationalized a translational medicine team and brings a wealth of research experience to LEO Pharma, including five years of basic research and more than 15 years of clinical research from different positions in the area of inflammatory diseases in the US and Europe.
“I am thrilled to join LEO Pharma at a time of break-through discoveries in multiple areas of skin biology and technology , providing unparalleled opportunities to drive innovation in dermatology for the benefit of patients world-wide,” said Thomas Hultsch, Head of Translational Medicine, LEO Pharma, Boston, MA.
For further information, please contact:
LEO Pharma A/S
Henrik Kyndlev, Global External Communications
Tel.: +45 3140 6180
Information om LEO Pharma
About LEO Pharma LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,700 people, serving 80 million patients in 130 countries. In 2017, the company generated net sales of euro 1.4 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
Forskere fra LEO Pharma hyldes med Innovationsfondens Innovatørpris 20191.2.2019 15:01:40 | Pressemeddelelse
Excellent og banebrydende forskning, som skaber værdi for Danmark, er i fokus, når Innovationsfonden i dag uddeler årets priser. Det er derfor med stor stolthed, at LEO Pharma i dag kan meddele, at to af virksomhedens forskere, Marianne Lind, Ph.d. Senior Scientist og Karsten Petersson, Ph.d. Director, er udvalgt til at modtage Innovatørprisen 2019. Det er tredje år i træk, at prisen uddeles, og tildelingen af årets Innovatørpris til Marianne Lind og Karsten Petersson, som begge arbejder inden Explorative Formulation & Technologies hos LEO Pharma, sker på baggrund af følgende vurderinger: Den værdiskabelse, kandidaterne har skabt for såvel virksomhed som patienter Kandidaternes evne til at omsætte excellent forskningsviden til konkrete løsninger De to forskere modtager prisen for udviklingen af Enstilar®, LEO Pharmas skumspray til behandling af psoriasis. Enstilar® blev godkendt af Lægemiddelstyrelsen og kom på markedet i Danmark i 2016. Produktet anvendes i dag af flere end en million
LEO Pharma Strengthens Focus on Translational Medicine with the Appointment of Adam B. Raff, M.D., Ph.D., as Director and Medical Advisor9.1.2019 10:23:45 | Pressemeddelelse
Ballerup, Denmark, 9 January, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that Adam B. Raff has been appointed as Director and Medical Advisor in Translational Medicine as of January 28, 2019. Adam Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine. Adam Raff is a Doctor of Medicine (Hons) and holds a Doctorate in Philosophy in Systems Biology and Disease from the University of Southern California in Los Angeles, CA as well as a Bachelor of Science in Biology (Hons) from Georgetown University in Washington, DC. He completed his dermatology training at the Harvard Combined Dermatology Residency Program, Boston, MA. In his current position, Adam Raff works as a Dermatologist at the Department of Dermatology at Massachusetts General Hospital, Boston, MA as well as a Dermatology Instructor at Harvard Medical School, Boston, MA. With the addition of a new Translational Medicin
LEO Pharma indgår samarbejde med amerikanske PellePharm og starter klinisk fase 3 forsøg i behandling af Gorlins Syndrom20.11.2018 12:00:00 | Pressemeddelelse
LEO Pharma A/S køber minoritetspost i amerikanske PellePharm og finansierer planlagt fase 3 forsøg i behandling af Gorlins Syndrom for USD70 mio. bestående af aktiekapital samt R&D-finansiering.
LEO Pharma and Zymeworks Enter into Bispecific Antibody Licensing and Research Collaboration23.10.2018 13:16:54 | Pressemeddelelse
The companies will collaborate on the discovery of novel monospecific antibodies to develop bispecific therapeutics targeting cytokine-receptor pathways with applications in dermatology, inflammation, and autoimmunity by leveraging Zymeworks’ Azymetric™ and EFECT™ therapeutic platforms.
World Psoriasis Day 2018: Psoriasis skal tages alvorligt22.10.2018 14:10:01 | Pressemeddelelse
Global kampagne fra LEO Pharma sætter fokus på psoriasis og hvordan sygdommen påvirker de 125 millioner mennesker, der er ramt af den(1)
LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics17.9.2018 22:34:44 | Pressemeddelelse
LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum